TY - JOUR
T1 - Perceptions and behaviours related to COVID-19 in patients with rheumatoid arthritis
T2 - a cross-sectional study
AU - Itaya, Takahiro
AU - Torii, Mie
AU - Hashimoto, Motomu
AU - Jindai, Kazuaki
AU - Yamamoto, Wataru
AU - Tanigawa, Kyosuke
AU - Urai, Yuki
AU - Kinoshita, Ayae
AU - Nin, Kazuko
AU - Watanabe, Ryu
AU - Murata, Koichi
AU - Murakami, Kosaku
AU - Tanaka, Masao
AU - Ito, Hiromu
AU - Matsuda, Shuichi
AU - Morinobu, Akio
N1 - Funding Information:
KURAMA cohort study is supported by a grant from Daiichi Sankyo. Daiichi Sankyo had no role in the study design, data collection or analysis, manuscript preparation or the decision to submit the manuscript for publication. This work was also supported by JSPS KAKENHI (Grant Number JP19K11165).
Funding Information:
Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co. and Asahi Kasei Pharma Corp.). MH received a research grant and/or speaker fee from Bristol-Myers, Eisai, Eli Lilly and Mitsubishi Tanabe Pharma. RW received speaker’s fee from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb and Janssen. KMurat received speaker fees from Eisai Co., Ltd. MTa received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Taisho Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd. HI received research grants and/or speaker fees from BMS, Kyocera, Asahi-Kasei, Eisai, Mochida and Toyama. SM received research grants and/or speaker fees from AYUMI Pharmaceutical Co., Pfizer Inc., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Kyocera, Chugai Pharmaceutical Co. Ltd., Mochida and Taisho Pharma Co., Ltd. AM received speaking fees and/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd. TI, MTo, WY, KT, YU, AK, KN, KJ and KMurak have declared no conflicts of interest.
Publisher Copyright:
© 2021, International League of Associations for Rheumatology (ILAR).
PY - 2022/1
Y1 - 2022/1
N2 - Objectives: To study the perceptions and behavioural changes related to the coronavirus disease 2019 (COVID-19) in patients with rheumatoid arthritis (RA) and determine their associations with patient characteristics, such as health literacy. Methods: This cross-sectional study was conducted from September to November of 2020 and included 400 outpatients with RA aged 18 and above. We measured self-reported perceptions as outcomes, such as awareness, knowledge and behaviours related to COVID-19. Health literacy and other characteristics as exposures were investigated using self-report questionnaires and electronic health records. To analyse the association between patient factors and the outcomes, multivariable linear and logistic regression models were performed. Results: In total, 365 patients completed the survey. More than half (51%) of patients reported that they were ‘very worried’ about possible infection with COVID-19, whereas over 80% believed the possibility of getting COVID-19 was low. In the multivariable analyses, patients with low health literacy had limited knowledge about COVID-19 and did not change daily routines and perform preventive measures. Conclusions: In this pandemic, healthcare providers may need to be aware of more vulnerable individuals and share COVID-19 related information promptly and effectively with their patients.Key Points• This cross-sectional study aimed to investigate the perceptions and behavioural changes related to COVID-19 in patients with RA.• All patients were aware of COVID-19 and most of them worried about getting infected.• Health literacy, age, sex, disease activity and rheumatic drugs were associated with perceptions and behaviours related to COVID-19.
AB - Objectives: To study the perceptions and behavioural changes related to the coronavirus disease 2019 (COVID-19) in patients with rheumatoid arthritis (RA) and determine their associations with patient characteristics, such as health literacy. Methods: This cross-sectional study was conducted from September to November of 2020 and included 400 outpatients with RA aged 18 and above. We measured self-reported perceptions as outcomes, such as awareness, knowledge and behaviours related to COVID-19. Health literacy and other characteristics as exposures were investigated using self-report questionnaires and electronic health records. To analyse the association between patient factors and the outcomes, multivariable linear and logistic regression models were performed. Results: In total, 365 patients completed the survey. More than half (51%) of patients reported that they were ‘very worried’ about possible infection with COVID-19, whereas over 80% believed the possibility of getting COVID-19 was low. In the multivariable analyses, patients with low health literacy had limited knowledge about COVID-19 and did not change daily routines and perform preventive measures. Conclusions: In this pandemic, healthcare providers may need to be aware of more vulnerable individuals and share COVID-19 related information promptly and effectively with their patients.Key Points• This cross-sectional study aimed to investigate the perceptions and behavioural changes related to COVID-19 in patients with RA.• All patients were aware of COVID-19 and most of them worried about getting infected.• Health literacy, age, sex, disease activity and rheumatic drugs were associated with perceptions and behaviours related to COVID-19.
KW - COVID-19
KW - Health knowledge
KW - Health literacy
KW - KURAMA cohort
KW - Rheumatoid arthritis
KW - attitudes
KW - practice
UR - http://www.scopus.com/inward/record.url?scp=85115858449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115858449&partnerID=8YFLogxK
U2 - 10.1007/s10067-021-05840-2
DO - 10.1007/s10067-021-05840-2
M3 - Article
C2 - 34581890
AN - SCOPUS:85115858449
VL - 41
SP - 45
EP - 51
JO - Clinical Rheumatology
JF - Clinical Rheumatology
SN - 0770-3198
IS - 1
ER -